Evidence map›Paper›PMID 39305094›Full record

ReviewJournal of cosmetic dermatology2024

The Effect of Botulinum Toxin Type A in the Autologous Fat Grafting: A Review.

Chihchieh Lo, Lideng Cao, Yuanyou Lin, Hang Wang

Abstract readReview
In one paragraph

Review in Journal of cosmetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chihchieh LoDepartment of Oral and Maxillofacial Surgery and State Key Laboratory of Oral Diseases, Sichuan University West China College of Stomatology, Chengdu, Sichuan, China.ORCID https://orcid.org/0009-0001-7377-6868
Lideng CaoDepartment of Oral and Maxillofacial Surgery and State Key Laboratory of Oral Diseases, Sichuan University West China College of Stomatology, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0001-7503-0050
Yuanyou LinDepartment of Oral and Maxillofacial Surgery and State Key Laboratory of Oral Diseases, Sichuan University West China College of Stomatology, Chengdu, Sichuan, China.
Hang WangDepartment of Oral and Maxillofacial Surgery and State Key Laboratory of Oral Diseases, Sichuan University West China College of Stomatology, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutologous fat grafting is a widely used technique in plastic and reconstructive surgery for soft tissue augmentation. Despite its advantages, the primary limitation is the unpredictable retention rate of transplanted fat. Recent studies suggest that botulinum toxin type A (BTX-A) can enhance fat graft survival by promoting angiogenesis and muscle paralysis.

aimsThis review explores the potential of BTX-A as an adjuvant in autologous fat grafting, providing insights into its mechanisms, benefits, and the need for further clinical validation. PATIENTS/

methodsA literature review was conducted using PubMed, Web of Science, MEDLINE, and Embase. Keywords related to BTX-A, fat grafting, fat graft survival, and angiogenesis were used. Comparative studies reporting histological changes following BTX-A application in fat grafting were included. Exclusion criteria involved case reports with fewer than three animals, reviews, and letters.

resultsThe initial search yielded 108 articles, with seven experimental studies meeting the criteria. These studies demonstrated that BTX-A enhances fat graft retention by promoting vascularization and adipose-derived stem cell differentiation. However, these results are mainly based on small animal models.

conclusionsWhile BTX-A shows promise in improving autologous fat grafting outcomes, its efficacy and safety in humans need validation through large-scale clinical trials. Translating these preclinical findings into human trials is crucial to establish standardized protocols and optimize clinical outcomes. Future research should focus on optimizing dosage and injection sites, conducting long-term follow-up studies, and performing multicenter trials to verify the findings.

Indexed as

Adipose TissueBotulinum Toxins, Type AGraft SurvivalTransplantation, AutologousAnimalsHumansNeovascularization, PhysiologicNeuromuscular AgentsBotulinum Toxins, Type ANeuromuscular Agentsadipocyte implantationangiogenesisbotulinum toxinfat grafting

Identifiers

PMID39305094
PMCPMC11626320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.